News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pro-Pharmaceuticals, Inc. (PRW) Collaborates with Numoda Corporation to Manage Phase III Clinical Trial to Increase Speed-to-Market for DAVANAT(R)



9/13/2010 9:50:56 AM

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANATĀ® and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES